Mayo Clinic Collaborates With PN Medical on a Research Study of Long COVID Patients

The clinical trial aims to identify solutions to combat the respiratory symptoms of post-acute COVID syndrome

PN Medical, a leading developer of cardiopulmonary training devices, is supporting Mayo Clinic in a clinical trial to identify new approaches to treat the symptoms of post-acute COVID syndrome (PACS). The COVID Virtual Recovery Study will focus on people who have tested positive for the SARS-CoV2 infection and have completed a 14-30 day quarantine.

A new study from the University of Oxford reports that more than one-third of COVID-19 patients may experience lingering symptoms for months following infection.1 Commonly referred to as Long COVID, some of the more common symptoms of post-acute COVID syndrome (PACS) include shortness of breath, fatigue, brain fog, loss of taste and smell, joint pain and depression. Health experts say the condition is clearly of public health concern, given the substantial impact it has on society, ranging from increased health care costs to economic and productivity losses.2

The goal of Mayo Clinic’s COVID Virtual Recovery Study is to investigate the benefits of respiratory muscle training (RMT) on strengthening the respiratory system and accelerating recovery from COVID-19. The findings will focus on functional recovery, mental wellbeing, and the ability to return to work or to pre-COVID daily activities.

“The respiratory system is central to a number of the lingering symptoms of long COVID,” explained Mark A. Carbone, CEO of PN Medical. “Implementing respiratory muscle training can positively impact the pathways involved in breathing and provide a gradual, progressive method to improve respiratory muscle function.”

The four-week study is completely virtual, allowing anyone in the U.S. who has been affected by COVID-19 to apply. Participants will receive PN Medical’s respiratory muscle training device (THE BREATHER or BREATHER FIT) and follow a training plan on the BREATHER COACH connected app that requires using the device up to two times a day on a specific number of days per week to test its effectiveness in reducing long COVID symptoms.

Interested persons can determine their eligibility and enroll in the COVID Virtual Recovery Study by visiting https://www.pnmedical.com/covid-virtual-recovery-study-cvrs-2/.

“PN Medical shares Mayo Clinic’s dedication to evidence-based science and cutting-edge research; in this case to develop drug-free solutions to help people improve their respiratory health,” said Carbone. “My hope is that this research study with Mayo Clinic will result in new protocols that lead to COVID resilience before, during and after positive exposure to the virus.”


References

  1. Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom
  2. Long COVID now has a formal definition. Here’s what you need to know

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.